Whilst cardiac hypertrophy is initially a compensatory response to the high blood pressure, the increased muscle mass outstrips its oxygen supply and coupled with the reduced coronary vascular reserve seen in hypertension, results in myocardial ischaemia even with normal coronary arteries. Thus beyond a certain point, left ventricular hypertrophy (LVH) secondary to hypertension becomes a major risk factor for myocardial infarction, stroke, sudden death, and congestive cardiac failure, 1 and this increased risk is in addition to that imposed by hypertension itself. Furthermore, hypertensives with LVH are at increased risk of cardiac arrhythmias (atrial fibrillation, ventricular arrhythmias) and atherosclerotic vascular disease (coronary and peripheral artery disease).
Whilst cardiac hypertrophy is initially a compensatory response to the high blood pressure, the increased muscle mass outstrips its oxygen supply and coupled with the reduced coronary vascular reserve seen in hypertension, results in myocardial ischaemia even with normal coronary arteries. Thus beyond a certain point, left ventricular hypertrophy (LVH) secondary to hypertension becomes a major risk factor for myocardial infarction, stroke, sudden death, and congestive cardiac failure, 1 and this increased risk is in addition to that imposed by hypertension itself. Furthermore, hypertensives with LVH are at increased risk of cardiac arrhythmias (atrial fibrillation, ventricular arrhythmias) and atherosclerotic vascular disease (coronary and peripheral artery disease). 1 Patients with hypertension and LVH should therefore be identified for aggressive management, not only of blood pressure, but of all their cardiovascular risk factors.
Epidemiological data regarding prevalence of LVH and the increased risk of cardiovascular mortality and morbidity was initially provided by the Framingham Heart Study more than 30 years ago, which employed ECG criteria to define LVH. 2 Conversely, the association between hypertension and LVH is also well-established, 3 leading to a particularly high cardiovascular risk for the uncontrolled hypertensive via the development of LVH. However, the correlation between blood pressures measured in the clinical environment and left ventricular mass is poor. 4 By contrast, 24-h ambulatory blood pressure monitoring (ABPM) provides a closer correlation between average daytime arterial blood pressure and left ventricular mass. 5 Many different criteria for identifying LVH exist, based on both echocardiographic (echo-LVH) and electrocardiographic (ECG-LVH) features, but there is considerable variation in sensitivity and specificity between these methods. 1, 6, 7 A commonly used screening test for LVH in hypertensives uses the 12-lead ECG and the Sokolow and Lyon criteria, that is, the sum of the S wave in lead V1 and the R wave in leads V5 or V6 on the ECG Ͼ35 mm, with a sensitivity of 22% and specificity of 79%. Other methods have also been evaluated: [6] [7] [8] [9] (i) The Romhilt-Estes Point-Score System of у4 has a sensitivity of 12% and specificity of 87%; (ii) The Cornell system has a sensitivity of 31% and specificity of 87%; (iii) the Sokolow-Lyon Index (RaVL у1.1 mV) has a sensitivity of 18% and specificity of 92%; and (iv) the Rodrigez Padial system has a sensitivity of 82% and specificity of 8% respectively. These figures suggest that most forms of interpreting the ECG with regards to LVH are not useful as a screening tool. This can be marginally improved by multiplying QRS-voltage by QRS-duration, thus increasing the specificity to 96% and sensitivity to about 50%. 6, 7 Crudely speaking, the features of LVH on ECG normally mean that true LVH is present, but its absence does not mean that LVH is absent. Nevertheless, the specificity of the ECG is relatively high (up to 98.8%), but appears to be lower in black populations than whites. 8, 9 The development of echocardiography has since provided an alternative method of identifying LVH. The recorded prevalence of LVH when applying echocardiographic criteria far exceeds that of ECG-LVH. For example, amongst 4684 subjects from Framingham who underwent echocardiography and ECG, echo-LVH was identified in 14.2% of men and 17.6% of women, compared with 2.9% and 1.5% respectively when ECG-LVH criteria were applied. 8, 9 Importantly, echocardiography demonstrates superior sensitivity over ECG in predicting anatomical LVH at necropsy, 1 with a sensitivity of 85-100%, compared to a sensitivity as low as 6% using ECG criteria. Echo-LVH has been shown to be as important as ECG-LVH as a prognostic marker for
Journal of Human Hypertension coronary artery disease, stroke and all-cause mortality. 10 Echo-LVH has also been shown to be associated with increased risk of sudden death, 11 probably via the development of ventricular arrhythmias, 12 which may itself be related to the increased QTc dispersion demonstrated on the electrocardiogram of patients with LVH. 13, 14 Echocardiography has thus become the current 'gold standard' for detection of LVH, despite some minor variations in recorded prevalence of LVH when differing echocardiographic diagnostic criteria are employed. 15 However, the high prevalence of hypertension in the community and the relatively limited provision of open-access echocardiography services (at least in the United Kingdom) may currently prevent many general practitioners from obtaining echocardiographic information on the majority of their hypertensive patients and, unless the situation changes, they shall need to continue to rely on the ECG for diagnosis of LVH. It is important, therefore, that they are fully aware of the potential advantages and limitations of using the ECG to identify LVH amongst hypertensive patients, in order that they may implement an appropriate strategy for identification and management of this high-risk group.
The apparent shortcomings of the ECG in identifying patients with LVH has led to a multitude of further studies seeking methods to improve the sensitivity of the ECG by accounting for potential confounding factors. Sensitivity of the ECG improves with advancing age, but is reduced by smoking, obesity and marginally in women. 8 Of the many methods of ECG analysis proposed for detection of LVH, sensitivity appears to be improved (possibly up to approximately 50%) by the Cornell product method, which accounts for both QRS voltage and duration, and sensitivity of this method also appears to be less influenced by body habitus than other methods, including the Framingham-adjusted Cornell voltage (which incorporates algorhythms to adjust for age, sex and body mass index in an attempt to improve ECG sensitivity) and SokolowLyon voltage methods. 9, 16 Despite the evidence for LVH as an independent cardiovascular risk factor, the study by Kumpusalo et al 17 in the current issue of Journal of Human Hypertension suggests that the majority of hypertensive patients with ECG-LVH may be under-treated, with adequate hypertension control being achieved in only 17% of hypertensives with ECG-LVH managed in general practice. Furthermore, using the sexspecific Cornell product, the prevalence of ECG-LVH amongst these Finnish hypertensives was high, at 14.9% of males and 18.8% of females. However, as we are not fully informed of the methods by which general practitioners identified their hypertensive patients for inclusion into the study, we cannot be absolutely sure that the sample group are truly representive of the hypertensive population of Finland as a whole. The patients with LVH had a longer duration of hypertensive history and less tight control of their blood pressure than the other hypertensives in the study, despite a similar drug treatment profile, perhaps suggesting more 'resistant' hypertension in this group. Whether the general practitioners were previously aware of the diagnosis of LVH in these patients is not made clear, and it would be interesting to know whether a knowledge of the presence of LVH would have led to increased efforts to achieve blood pressure control.
The conclusions which can be drawn from the study by Kumpusalo et al 17 are that routine ECG screening for LVH amongst hypertensives has the potential to identify a relatively large proportion of individuals with this additional risk factor for cardiovascular morbidity and mortality, who may then require particularly aggressive antihypertensive therapy to achieve target blood pressure. Epidemiological studies suggest that the prevalence of LVH is currently declining in proportion to the increasing use of antihypertensives and resulting fall in mean systolic and diastolic blood pressure. 3 Several prospective studies have also demonstrated that echocardiographically determined left ventricular mass can be reduced by the use of standard antihypertensive therapies, although the benefits may be greatest with ACE-inhibitor therapy, 18 and both ACE inhibitors and calcium antagonists have also been shown to reduce the degree of QTc dispersion together with LV mass. 19, 20 Although there is currently a paucity of data correlating LVH regression with long-term outcome, a review of the available data suggests a lower morbidity in individuals with LVH regression than those in whom LVH progresses. 21 The need for a prospective controlled study of antihypertensive therapy in LVH patients, combining mortality and morbidity endpoints with ECG and echocardiographic assessment of LVH, is currently being addressed by the LIFE study, 22 investigating the potential role of the angiotensin II type 1 receptor antagonist, losartan, in hypertensive patients with LVH.
Whilst it is clear that the ECG is an imperfect tool for the identification of LVH, the general availability of electrocardiography, coupled with the relatively high test specificity and improving sensitivity (with newer methods of analysis), make it a useful tool for the general practitioner. Whilst there is still a lot to be learned about the relationship between hypertension, LVH and cardiovascular disease, general practitioners should exercise vigilance for the presence of ECG-LVH amongst their hypertensive patients, in order to target aggressive coronary risk factor modification and make strenuous efforts to achieve control of hypertension.
